Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

A partir d'échantillons de tumeurs primitives et de métastases prélevés sur 68 patients atteints d'un adénocarcinome canalaire du pancréas, cette étude identifie un ensemble d'anomalies génomiques

Résumé en anglais

Background: Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with complex genomes and dense fibrotic stroma. This study was designed to identify clinically relevant somatic aberrations in pancreatic cancer genomes of patients with primary and metastatic disease enrolled and treated in two clinical trials.

Methods: Tumour nuclei were flow sorted prior to whole genome copy number variant (CNV) analysis. Targeted or whole exome sequencing was performed on most samples. We profiled biopsies from 68 patients enrolled in two Stand Up to Cancer (SU2C)-sponsored clinical trials. These included 38 resected chemoradiation naïve tumours (SU2C 20206-003) and metastases from 30 patients who progressed on prior therapies (SU2C 20206-001). Patient outcomes including progression-free survival (PFS) and overall survival (OS) were observed.

Results: We defined: (a) CDKN2A homozygous deletions that included the adjacent MTAP gene, only its’ 3′ region, or excluded MTAP; (b) SMAD4 homozygous deletions that included ME2; (c) a pancreas-specific MYC super-enhancer region; (d) DNA repair-deficient genomes; and (e) copy number aberrations present in PDA patients with long-term (greater than or equal to 40 months) and short-term (less than or equal to 12 months) survival after surgical resection.

Conclusions: We provide a clinically relevant framework for genomic drivers of PDA and for advancing novel treatments.